Protocol Ledger

NCT04208646 · Phase II · COMPLETED

Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

Interventional Phase II clinical trial protocol NCT04208646 sponsored by Shanghai AbelZeta in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-16 Enrollment: 106 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04208646
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)106 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04208646
Protocol FieldVerified Registry Value
NCT IdentifierNCT04208646
Consolidated Lead SponsorShanghai AbelZeta
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment106 participants (ACTUAL)
Registered Start Date2020-05-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI